Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
81,000
Employees81,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
81,000
Employees81,000

PFE Key Statistics

Market cap
143.71B
Market cap143.71B
Price-Earnings ratio
14.85
Price-Earnings ratio14.85
Dividend yield
6.75%
Dividend yield6.75%
Average volume
40.97M
Average volume40.97M
High today
$25.77
High today$25.77
Low today
$25.09
Low today$25.09
Open price
$25.58
Open price$25.58
Volume
50.26M
Volume50.26M
52 Week high
$27.69
52 Week high$27.69
52 Week low
$20.92
52 Week low$20.92

Stock Snapshot

With a market cap of 143.71B, Pfizer(PFE) trades at $25.31. The stock has a price-to-earnings ratio of 14.85 and currently yields dividends of 6.8%.

On 2026-01-13, Pfizer(PFE) stock moved within a range of $25.09 to $25.77. With shares now at $25.31, the stock is trading +0.9% above its intraday low and -1.8% below the session's peak.

Trading volume for Pfizer(PFE) stock has reached 50.26M, versus its average volume of 40.97M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.

PFE News

TipRanks 12h
Pfizer CEO says ‘not in our plans’ to do buybacks

13:31 EST Pfizer (PFE) CEO says ‘not in our plans’ to do buybacks Claim 70% Off TipRanks Premium Published first on TheFly – the ultimate source for real-time...

TipRanks 12h
Pfizer CEO sees launching 10 Phase 3 GLP-1 trials this year

13:06 EST Pfizer (PFE) CEO sees launching 10 Phase 3 GLP-1 trials this year Published first on TheFly – the ultimate source for real-time, market-moving breaki...

Benzinga 14h
Pfizer Cancer Combo Drug Shows Strong Tumor Shrinkage in Colorectal Cancer Trial

On Saturday, Pfizer Inc. (NYSE:PFE) shared data from Cohort 3 of the BREAKWATER trial. The Phase 3 BREAKWATER trial evaluated Braftovi (encorafenib) with cetux...

Pfizer Cancer Combo Drug Shows Strong Tumor Shrinkage in Colorectal Cancer Trial

Analyst ratings

57%

of 28 ratings
Buy
39.3%
Hold
57.1%
Sell
3.6%

More PFE News

TipRanks 14h
Pfizer’s New Colorectal Cancer Trial Puts PF-08634404 Head-to-Head With a Market Standard

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview This Phase 3 Pfizer study, officially tit...

TipRanks 14h
Pfizer’s Phase 3 C. Difficile Vaccine Study Targets a New Niche in the Adult Vaccine Market

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...

Simply Wall St 22h
Pfizer Valuation Check After Positive BREAKWATER Oncology Trial Update

Pfizer (PFE) is back in the oncology spotlight after reporting favorable Cohort 3 data from its pivotal BREAKWATER trial, where a regimen of BRAFTOVI, cetuximab...

Pfizer Valuation Check After Positive BREAKWATER Oncology Trial Update
The Motley Fool 4d
Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026

It could be another tough year for the once-soaring drugmaker. Pfizer's (PFE +0.81%) shares have been southbound for the last three years. And unfortunately fo...

Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026
TipRanks 4d
Madrigal Pharmaceuticals expands MASH pipeline with global license agreement

Madrigal Pharmaceuticals (MDGL) announced an exclusive global license agreement with Pfizer (PFE) for ervogastat, a clinical-stage oral DGAT-2 inhibitor, streng...

The Motley Fool 5d
Want Over $2,000 in Dividends Each Year? Invest $12,000 Each Into These 3 Stocks

These high-yielding dividend stocks pay 5% or more, and make for safe income investments to hold on to. Dividend stocks can be the ultimate investments to buy...

Want Over $2,000 in Dividends Each Year? Invest $12,000 Each Into These 3 Stocks
Simply Wall St 5d
Does Pfizer Offer Long Term Value After A 36% Three Year Share Price Slide

If you are wondering whether Pfizer's current share price offers good value, this article will walk through what the latest data suggests and how to think about...

Does Pfizer Offer Long Term Value After A 36% Three Year Share Price Slide

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.